The insider sales are routine and negligible. The debt amendment extends cash runway into 2028, a modest positive for a pre-revenue biotech. No actionable trading signal from the cluster alone, monitor upcoming clinical catalysts for IRON.
IRON drugs
IRON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 1 $74.95entry
- T+1 · 5mo ago +1.75%α +1.88% · $76.26
- T+5 · 4mo ago +6.42%α +6.16% · $79.76
- T+20 · 4mo ago −1.71%α +0.48% · $73.67
- T+60 · 8w ago −11.35%α −14.23% · $66.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite insiders at Disc Medicine (IRON) sold a total of $209K in open-market shares over a 4-day window, all via same-day option exercises. The sales represent just 0.0075% of the $2.8B market cap, making them trivial. Concurrently, the company filed an 8-K amending its Hercules loan to draw $30M and extend draw periods through 2028, modestly improving liquidity. The insider activity carries no material signal.
Key Financial Metrics
Key Facts
- Total open-market sales of $209K by CLO Khara Rahul and COO Jonathan Yu over June 26–29, 2026
- All sales were same-day option exercises (exercise prices $0–$14.69), routine liquidity events
- Sales represent ~0.0075% of IRON's $2.8B market cap, well below the 0.1% materiality threshold
- On June 30, 2026, Disc Medicine filed an 8-K amending its Hercules loan: $30M immediate drawdown, extended draw periods through 2028, and relaxed minimum cash covenant to July 2028
Financial Impact
Insider sales of $209K are immaterial relative to $2.8B market cap; debt amendment provides up to $30M additional liquidity
Risk Factors
- Insider sales are small and likely tax-driven; no bearish signal
- Debt amendment increases leverage but extends runway, neutral for equity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IRON-1782856303873 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers